We are international
Donate
TEXT SIZE   


ASH 2012: Dr. Berdeja - Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)
Jesus Berdeja, MD
Sarah Cannon Research Institute
Nashville, Tennessee
12.02.12


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles